Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.
CSPC Pharmaceutical Group has announced that its new chemical drug, SYH2056 tablets, a selective 5-HT2A receptor agonist, has received approval for clinical trials in China. This drug, aimed at treating depression, shows promise due to its rapid action, long-lasting effects, and reduced hallucination risk, potentially positioning it as a best-in-class antidepressant. The approval marks a significant step in addressing the limitations of traditional antidepressants and meeting the high clinical demand for novel depression therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, incorporated in Hong Kong, operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is known for its research and development of new chemical drugs, with a market focus on addressing unmet clinical needs.
Average Trading Volume: 147,790,246
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.08B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.